Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05628363 · ClinicalTrials.gov registry record · NA

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

A NA study of Prostate Cancer and Cancer of the Prostate, sponsored by Washington University School of Medicine.

Active
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT05628363 is a NA study of Prostate Cancer and Cancer of the Prostate that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 28 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05628363, a NA study of Prostate Cancer and Cancer of the Prostate, is active but no longer recruiting, sponsored by Washington University School of Medicine.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic body radiation therapy (SBRT) with a tumor boost to the magnetic resonance (MR)-detected sites of disease. The hypothesis is that this treatment approach will be safe and feasible with \<15% of patients experiencing an acute CTCAEv5 grade ≥3 genitourinary (GU) or gastrointestinal (GI) adverse event.

Interventions

  • DRUG Androgen deprivation therapy
  • DEVICE Ethos Varian treatment system
  • RADIATION Adaptive stereotactic body radiotherapy

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-01-18
Est. Completion 2030-07-25
Phase NA

What the Registry Record Tells You About NCT05628363

The ClinicalTrials.gov registry entry for NCT05628363 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Androgen deprivation therapy is the first listed.

NCT05628363 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT05628363 about?

NCT05628363 is a clinical study titled "Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer". This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic body radiation therapy (SBRT) with a tumor boost to the magnetic resonance (MR)-detected sites of disease. The hypothesis is that this treatment approach will ...

What is the current status of trial NCT05628363?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2023-01-18. Estimated completion is 2030-07-25.

What conditions does trial NCT05628363 study?

This clinical trial studies the following conditions: Prostate Cancer, Cancer of the Prostate.

What interventions are being tested in trial NCT05628363?

The interventions under investigation include: Androgen deprivation therapy (DRUG), Ethos Varian treatment system (DEVICE), Adaptive stereotactic body radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT05628363?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05628363 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.